Liquidia falls as rival Merck's therapy for lung condition gets FDA approval

Liquidia

27/03/2024 14:39

** Shares of Liquidia  LQDA.O  fall ~5.7% to $15.01
    ** The U.S. FDA approved Merck's  MRK.N  treatment for
adults with pulmonary arterial hypertension (PAH), late on
Tuesday
    ** Liquidia has said the FDA was still reviewing its PAH
inhaled drug yutrepia, decision on which was due on Jan. 24 
    ** Last month, United Therapeutics  UTHR.O  said it had
filed a case with the FDA alleging that due procedure was not
followed in allowing rival Liquidia's application for the drug
    ** PAH is caused by a constriction of arteries in the lungs,
leading to high blood pressure and symptoms such as shortness of
breath, chest pain and dizziness
    ** LQDA stock more than doubled in the last 12 months

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))